SCHEMBL2336470

SCHEMBL2336470

FC1CCN(c2nc3c(c(-c4ccc(Cl)c(Cl)c4)n2)CCNCC3)CC1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 15/20 0.43
HTR2A P28223 15/20 0.43
HTR2B P41595 12/20 0.43
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 1/20 0.37
S1PR2 O95136 1/20 0.37
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.37
HRH4 Q9H3N8 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2339041 0.92 HTR2C (0.46) HTR2CHTR2AHTR2BNPSR1KDM4E
SCHEMBL2343409 0.88 HTR2C (0.57) HTR2CHTR2AHTR2BNPSR1KDM4E
SCHEMBL2338980 0.83 HTR2C (0.58) HTR2CHTR2AHTR2BKDM4EALDH1A1
SCHEMBL2341735 0.80 HTR2C (0.60) HTR2CHTR2AHTR2BKDM4EKMT2A
SCHEMBL2344862 0.80 HTR2A (0.45) HTR2CHTR2AHTR2BNPSR1ALDH1A1
SCHEMBL2343222 0.79 HTR2C (0.49) HTR2CHTR2AHTR2B
SCHEMBL3379796 0.78 HTR2A (0.47) HTR2CHTR2AHTR2BKDM4EKMT2A
SCHEMBL12449411 0.78 HTR2C (0.38) HTR2CHTR2AHTR2BNPSR1KDM4E
SCHEMBL2340772 0.76 HTR2C (0.60) HTR2CHTR2AHTR2BNPSR1KDM4E
SCHEMBL2342275 0.76 HTR2C (0.46) HTR2CHTR2AHTR2BNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 US claimed
US-8829011-B2 2-aminopyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-09-09 US disclosed
US-8829011-B2 2-aminopyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-09-09 US disclosed
US-8829011-B2 2-aminopyrimidine compounds as serotonin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-09-09 US disclosed
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 US disclosed
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 US disclosed
WO-2010053825-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207717-A1 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS HTR2A, HTR6, HTR5A HTR2C 6/4885HTR2A 1/4885HTR2B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.